The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials
Background Whether combined CsA with androgen therapy was superior to androgen therapy alone in NSAA remains controversial. This study aimed to assess the efficacy and safety of combined therapy versus androgen therapy for NSAA patients using a meta-analytic approach.Methods An electronic database o...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2022.2081008 |
| _version_ | 1818207276590170112 |
|---|---|
| author | Xiao-tian Zhang Ya-nan Zhang Jing-jing Zhu Xue Wang Jiang Cao Wei Chen Na Qi Kai-lin Xu Hai Cheng |
| author_facet | Xiao-tian Zhang Ya-nan Zhang Jing-jing Zhu Xue Wang Jiang Cao Wei Chen Na Qi Kai-lin Xu Hai Cheng |
| author_sort | Xiao-tian Zhang |
| collection | DOAJ |
| description | Background Whether combined CsA with androgen therapy was superior to androgen therapy alone in NSAA remains controversial. This study aimed to assess the efficacy and safety of combined therapy versus androgen therapy for NSAA patients using a meta-analytic approach.Methods An electronic database of PubMed, EmBase, Cochrane library, CNKI, VIP, and Wanfang was systematically searched for randomized controlled trials (RCTs) from their inception to February 2020. The primary endpoint was effective rate, while the secondary endpoints included white blood cell (WBC), hemoglobin, platelet, and potential adverse events. The pooled results from included trials were calculated with the random-effects model.Results Forty-three RCTs recruited 2610 NSAA patients for the final quantitative meta-analysis. We noted that combined therapy was associated with an increased incidence of effective rate than androgen therapy alone (relative risk [RR]: 1.35; 95% confidence interval [CI]: 1.29–1.41; P < 0.001). Moreover, patients treated with combined therapy were associated with higher WBC (weighted mean difference [WMD]: 1.22; 95%CI: 0.94–1.49; P < 0.001), hemoglobin (WMD: 12.93; 95%CI: 8.86–17.01; P < 0.001), and platelet (WMD: 8.65; 95%CI: 7.05–10.24; P < 0.001). Finally, the pooled incidence of hirsutism, handshake, gingiva hyperplasia, liver function damage, and renal function damage were 0.35 (95%CI: 0.22–0.48), 0.24 (95%CI: 0.15–0.32), 0.22 (95%CI: 0.10–0.35), 0.19 (95%CI: 0.14–0.25), and 0.06 (95%CI: 0.01–0.11), respectively.Conclusions This study found that combined CsA with androgen therapy was superior to androgen therapy alone for Chinese patients with NSAA, and the most common adverse of combined therapy included hirsutism, handshake, gingiva hyperplasia, liver function damage, and renal function damage. |
| first_indexed | 2024-12-12T04:26:21Z |
| format | Article |
| id | doaj.art-e4afe2ef18df476194a2ff9b126df18a |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2024-12-12T04:26:21Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-e4afe2ef18df476194a2ff9b126df18a2022-12-22T00:38:12ZengTaylor & Francis GroupHematology1607-84542022-12-0127173374110.1080/16078454.2022.2081008The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trialsXiao-tian Zhang0Ya-nan Zhang1Jing-jing Zhu2Xue Wang3Jiang Cao4Wei Chen5Na Qi6Kai-lin Xu7Hai Cheng8Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaDepartment of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of ChinaBackground Whether combined CsA with androgen therapy was superior to androgen therapy alone in NSAA remains controversial. This study aimed to assess the efficacy and safety of combined therapy versus androgen therapy for NSAA patients using a meta-analytic approach.Methods An electronic database of PubMed, EmBase, Cochrane library, CNKI, VIP, and Wanfang was systematically searched for randomized controlled trials (RCTs) from their inception to February 2020. The primary endpoint was effective rate, while the secondary endpoints included white blood cell (WBC), hemoglobin, platelet, and potential adverse events. The pooled results from included trials were calculated with the random-effects model.Results Forty-three RCTs recruited 2610 NSAA patients for the final quantitative meta-analysis. We noted that combined therapy was associated with an increased incidence of effective rate than androgen therapy alone (relative risk [RR]: 1.35; 95% confidence interval [CI]: 1.29–1.41; P < 0.001). Moreover, patients treated with combined therapy were associated with higher WBC (weighted mean difference [WMD]: 1.22; 95%CI: 0.94–1.49; P < 0.001), hemoglobin (WMD: 12.93; 95%CI: 8.86–17.01; P < 0.001), and platelet (WMD: 8.65; 95%CI: 7.05–10.24; P < 0.001). Finally, the pooled incidence of hirsutism, handshake, gingiva hyperplasia, liver function damage, and renal function damage were 0.35 (95%CI: 0.22–0.48), 0.24 (95%CI: 0.15–0.32), 0.22 (95%CI: 0.10–0.35), 0.19 (95%CI: 0.14–0.25), and 0.06 (95%CI: 0.01–0.11), respectively.Conclusions This study found that combined CsA with androgen therapy was superior to androgen therapy alone for Chinese patients with NSAA, and the most common adverse of combined therapy included hirsutism, handshake, gingiva hyperplasia, liver function damage, and renal function damage.https://www.tandfonline.com/doi/10.1080/16078454.2022.2081008Cyclosporine Aandrogennon-severe aplastic anemia |
| spellingShingle | Xiao-tian Zhang Ya-nan Zhang Jing-jing Zhu Xue Wang Jiang Cao Wei Chen Na Qi Kai-lin Xu Hai Cheng The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials Hematology Cyclosporine A androgen non-severe aplastic anemia |
| title | The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials |
| title_full | The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials |
| title_fullStr | The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials |
| title_full_unstemmed | The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials |
| title_short | The efficacy and safety of cyclosporine A plus androgen versus androgen alone for adult patients with non-severe aplastic anemia in China: a meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of cyclosporine a plus androgen versus androgen alone for adult patients with non severe aplastic anemia in china a meta analysis of randomized controlled trials |
| topic | Cyclosporine A androgen non-severe aplastic anemia |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2022.2081008 |
| work_keys_str_mv | AT xiaotianzhang theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT yananzhang theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT jingjingzhu theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT xuewang theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT jiangcao theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT weichen theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT naqi theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT kailinxu theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT haicheng theefficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT xiaotianzhang efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT yananzhang efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT jingjingzhu efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT xuewang efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT jiangcao efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT weichen efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT naqi efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT kailinxu efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials AT haicheng efficacyandsafetyofcyclosporineaplusandrogenversusandrogenaloneforadultpatientswithnonsevereaplasticanemiainchinaametaanalysisofrandomizedcontrolledtrials |